 Pharmacor --
June 2005
 You Need to Know
How will the approval of bortezomib
as a second-line therapy affect its sales and the sales of other agents? Thalidomide-derived
immunomodulatory drugs (IMiDs) will take significant market share from
thalidomide—what other drug classes stand to lose? Will stem-cell transplantation
become more or less important in the next five years?
Introduction
Multiple myeloma (MM) is an
incurable hematologic cancer associated with extremely high morbidity and
mortality; curative therapy is the greatest unmet need. Our research reveals
that advances in the understanding of MM
Key Findings
 In 2004, incident cases of MM totaled more than 30,000; the
incident population will grow modestly during our forecast period due to the
aging of the population in all countries under study. Sales growth will be robust,
owing to the launch of emerging agents and the use of more aggressive
combinations of established and novel drugs.
Curative therapy is the greatest unmet need in the treatment of
MM. Most patients die within three years of diagnosis.
Immunomodulatory agents will take significant market share as
existing and emerging agents of this class steal share from older therapies
that offer only disappointing survival gains.
Why Buy This Report?
Discover how the wealth of new discoveries in the pathophysiology
of MM is affecting R&D programs--how long until the next generation of
targeted agents launches.
Explore striking regional differences in MM prescribing habits.
Uncover the shifting attitudes toward therapy for asymptomatic
MM.
Understand how cost constraints influence the use of key drug
classes.
|
